Clinical Trials Browser

Phase 2 × INDUSTRY × Meningioma × Clear all

Meningioma

NCT07428616 2026-02-24

A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

Phase 2 Not yet recruiting

100 enrolled

CNS

Brain Neoplasms, Meningioma

NCT06322342 2025-12-26

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

Phase 2 Completed

18 enrolled

CNS

Neuroinflammatory Diseases, Brain Neoplasms, Glioma, Meningioma, Multiple Sclerosis, Neoplasms, Neurilemmoma, Neurofibroma, Neuroma, Acoustic, Central Nervous System Neoplasms

Clinical Trials

A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma

A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent